title: Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
abstract: Background/Aims Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a newly identified biological agent has shown promising antitumor effects in a wide range of cancers. However, gastric cancer cells are less sensitive than other cancer cells to TRAIL-induced apoptosis.Here, we combined TRAIL with bortezomib, a proteasomal inhibitor to induce apoptosis in three gastric cancer cell lines.Methods After the cells were treated with TRAIL and/or bortezomib, the cell viability, apoptosis and cell cycle distribution were examined. The levels of death receptors and the mitochondrial membrane potential were also detected. The expression of apoptosis-associated proteins was determined by Western blot.Results Bortezomib at low concentration significantly(P<0.05) enhanced the cytotoxic effect of TRAIL by enhancing apoptosis as well as cell cycle arrest at G2/M phase. The enhancement of efficiency of TRAIL by bortezomib involved up-regulation of death receptor 4 and 5, as well as reduction of the mitochondrial membrane potential. Further study showed that combined treatment with TRAIL and bortezomib down-regulated anti-apoptotic protein cIAP-1, and over expression of cIAP-1 significantly(P\0.05) reduced the synergistic effect between TRAIL and bortezomib.Conclusions Bortezomib synergizes TRAIL-induced apoptosis in human gastric cancer cells. The synergistic effect between these two drugs is associated with up-regulation of death receptors and down-regulation of cIAP-1.The combination of TRAIL and bortezomib might be an effective regimen for the treatment of advanced gastric cancer.
authors.affiliation: Department of Medical Oncology, The First Hospital of China Medical University, 110001 Shenyang, People’s Republic of China. liujing_cmu@hotmail.com
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Xiu-Juan
authors.initials: XJ
authors.lastname: Qu
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Ye
authors.initials: Y
authors.lastname: Zang
authors.forename: Jing-Lei
authors.initials: JL
authors.lastname: Qu
authors.forename: Ke-Zuo
authors.initials: KZ
authors.lastname: Hou
authors.forename: Yun-Peng
authors.initials: YP
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D011719:Pyrazines / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D000069286:Bortezomib
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5000-5
references.pmid: 18698017
references.citation: FEBS Lett. 2009 Mar 4;583(5):943-8
references.pmid: 19223002
references.citation: J Clin Endocrinol Metab. 2007 May;92(5):1938-42
references.pmid: 17327374
references.citation: Oncogene. 2003 Nov 24;22(53):8628-33
references.pmid: 14634624
references.citation: Oncogene. 2004 Jul 15;23(32):5415-25
references.pmid: 15094781
references.citation: Nat Med. 1999 Feb;5(2):157-63
references.pmid: 9930862
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9394-407
references.pmid: 16361639
references.citation: Oncol Rep. 2007 Jul;18(1):71-6
references.pmid: 17549348
references.citation: Biochem Pharmacol. 2009 Mar 1;77(5):804-12
references.pmid: 19100720
references.citation: Br J Haematol. 2007 Sep;138(6):783-91
references.pmid: 17760810
references.citation: Immunity. 1995 Dec;3(6):673-82
references.pmid: 8777713
references.citation: Cancer Res. 2005 Mar 15;65(6):2344-52
references.pmid: 15781649
references.citation: Biochem Biophys Res Commun. 2007 Oct 12;362(1):218-223
references.pmid: 17706603
references.citation: Mol Cancer Ther. 2007 Sep;6(9):2591-9
references.pmid: 17876056
references.citation: Expert Opin Investig Drugs. 2008 Jun;17(6):879-95
references.pmid: 18491989
references.citation: Cancer Lett. 2007 Nov 8;257(1):56-64
references.pmid: 17689858
references.citation: J Immunol. 2001 May 1;166(9):5337-45
references.pmid: 11313369
references.citation: Cancer Biol Ther. 2005 Jul;4(7):781-6
references.pmid: 16082182
references.citation: J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44
references.pmid: 8230264
references.citation: Nature. 1998 Dec 10;396(6711):580-4
references.pmid: 9859993
references.citation: Carcinogenesis. 2007 Oct;28(10):2114-21
references.pmid: 17548900
references.citation: Drug Resist Updat. 2004 Dec;7(6):345-58
references.pmid: 15790545
references.citation: J Clin Invest. 1999 Jul;104(2):155-62
references.pmid: 10411544
references.citation: Am J Transl Res. 2009;1(1):1-15
references.pmid: 19966933
references.citation: Apoptosis. 2007 Apr;12(4):635-55
references.pmid: 17252198
references.citation: Cancer Res. 2007 May 15;67(10):4981-8
references.pmid: 17510429
references.citation: Cancer Res. 2007 Jul 15;67(14):6946-55
references.pmid: 17638906
references.citation: Cancer Sci. 2003 Dec;94(12):1066-73
references.pmid: 14662022
references.citation: Cell Signal. 2007 Nov;19(11):2237-46
references.pmid: 17693058
references.citation: Blood. 2003 Feb 1;101(3):1164-71
references.pmid: 12393423
references.citation: Mol Cancer Ther. 2005 Mar;4(3):443-9
references.pmid: 15767553